Olympus issues global labeling update for bronchoscopes after new injuries tied to laser and cautery use

Olympus Corporation has launched a global medical device corrective action to update its bronchoscope instructions following a series of injury reports involving laser therapy, argon plasma coagulation, and high-frequency cauterization. This Olympus bronchoscope labeling update replaces an earlier 2023 communication and introduces stricter bronchoscope procedural safety protocols for use during therapeutic airway procedures.

The decision was prompted by new clinical findings and incident reports, including four serious injury cases and one recent case from the United States. Olympus Corporation, a global leader in medical endoscopy systems, is calling on all healthcare institutions to immediately review and adopt the revised guidelines, which include more granular instructions for minimizing the risk of endobronchial combustion.

This update reinforces the company’s commitment to procedural safety in high-risk airway interventions, particularly when laser therapy in bronchoscopy is performed under elevated oxygen levels or in close proximity to heat-generating equipment.

Why is Olympus updating its bronchoscope usage instructions again in 2025?

Olympus Corporation had initially issued a medical device corrective action in 2023 after receiving reports of serious injuries and one death linked to the use of its bronchoscopes during laser and cauterization procedures. Despite that intervention, subsequent post-market surveillance between 2023 and 2025 revealed that bronchoscope injury incidents continued to occur due to inadequate compliance with earlier usage guidelines.

The new reports included four serious injuries, with one case emerging in the United States in early 2025. Olympus determined that further clarification was needed to ensure users fully understood how to prevent endobronchial combustion risks when combining its bronchoscopes with energy-based instruments like lasers or argon plasma coagulators.

Olympus emphasized that although no devices are being recalled, the labeling update should be treated as a critical safety step and incorporated into all bronchoscopy workflows involving therapeutic energy application. The company issued a formal communication to global customers in September 2025, detailing these new instructions for use updates.

What specific safety protocols has Olympus Corporation recommended in its latest guidance?

The revised Olympus bronchoscope instructions for use include highly specific parameters for clinicians performing airway procedures with energy-based equipment. Olympus now recommends maintaining at least four centimeters of distance between the bronchoscope and the endotracheal tube. Oxygen levels must be kept below 40 percent to reduce the chance of combustion during high-frequency cauterization or argon plasma coagulation with bronchoscope systems.

The energy output from devices such as laser probes and electrosurgical tools should remain under 40 watts, and excessive energy concentration on a single point in the airway should be avoided. Clinicians are also advised to employ suction actively to clear smoke and combustible gases during the procedure.

These new instructions are aimed at curbing the possibility of endobronchial combustion, a condition that can cause severe internal burns to the airways and lungs, sometimes requiring ICU admission or emergency surgical intervention. Olympus Corporation further warned that combustion events may damage bronchoscope equipment itself, resulting in fragments potentially being retained inside the patient.

How should hospitals implement Olympus Corporation’s updated bronchoscope safety guidelines?

Hospitals and outpatient clinics using Olympus Corporation’s devices are now expected to enforce updated bronchoscope procedural safety protocols without delay. This includes revising internal training programs, updating operating room checklists, and integrating the revised instructions for use update into clinical governance systems.

Olympus Corporation has called on all medical personnel—especially those involved in interventional pulmonology, thoracic surgery, and airway tumor ablation—to undergo retraining to reflect the new recommendations. Healthcare administrators are also being urged to assess the compatibility of all energy-based accessories being used alongside Olympus bronchoscopes, as improper integration of third-party devices has been associated with combustion risks.

Olympus has made it clear that its revised bronchoscope labeling update should be treated as essential for maintaining compliance with international patient safety standards. Institutions that fail to implement the revised safety protocols may face increased liability in the event of a procedural injury.

What are the legal and clinical risks if Olympus bronchoscope safety guidance is ignored?

Endobronchial combustion events, while rare, are considered high-risk and can have catastrophic outcomes. These include prolonged hospital stays, permanent respiratory damage, and in some cases, death. Olympus Corporation’s updated labeling places a stronger obligation on clinical users to prevent these risks by adhering to equipment usage instructions.

If hospitals ignore the updated Olympus bronchoscope safety guidelines, they could face both regulatory scrutiny and potential legal consequences. Under U.S. Food and Drug Administration guidelines and European Medical Device Regulation frameworks, updated labeling—especially when part of a formal medical device corrective action—is treated as binding in clinical practice.

The failure to implement such protocols could expose institutions to civil claims or procurement penalties, particularly if adverse events occur in the presence of non-compliance.

What is the broader impact of this Olympus labeling update on the medical device industry?

This case has amplified ongoing discussions around real-time post-market surveillance and dynamic safety labeling within the global medical device ecosystem. Olympus Corporation’s labeling revisions align with a larger industry trend of issuing corrective actions based on real-world evidence, rather than waiting for cumulative damage to warrant product recalls.

Regulators, including the U.S. Food and Drug Administration and corresponding European agencies, have welcomed such moves as part of risk-mitigation strategies in complex surgical environments. Clinical institutions are expected to treat updated labeling with the same weight as regulatory advisories or black box warnings in pharmaceutical practice.

Olympus Corporation’s revised bronchoscope guidance also raises expectations for future device manufacturers to maintain tight integration between product design, user education, and energy-based procedural safety.

Will Olympus Corporation’s market position be impacted by the bronchoscope injury incidents?

Olympus Corporation remains one of the most recognized names in endoscopic systems globally. Despite the recent injury reports, the Olympus bronchoscope product line continues to be widely used due to its imaging quality, advanced features, and reliability.

However, reputational sensitivity around procedural safety has grown, and institutional sentiment now favors companies that not only build technically sound devices but also invest heavily in user training and post-market responsiveness. Olympus Corporation’s proactive move to revise its bronchoscope safety labeling may be seen as a quality-enhancing measure rather than a weakness, provided no further incidents arise.

Still, hospitals and procurement teams are expected to monitor compliance performance metrics closely. If combustion incidents persist, Olympus could face additional scrutiny or even procurement re-evaluation in high-volume markets.

What must healthcare providers do now to comply with the Olympus bronchoscope labeling update?

Clinicians and biomedical engineers must immediately consult the September 2025 customer letter, which outlines the full scope of Olympus Corporation’s instructions for use update. This includes verifying all oxygen flow parameters, calibrating energy-based tools, and ensuring that clinical teams are retrained to understand the spatial and energy limitations of bronchoscopic interventions.

Hospitals are encouraged to document internal training updates, integrate changes into electronic health records, and establish new procedural checklists specifically for laser therapy in bronchoscopy, argon plasma coagulation, and high-frequency cauterization.

Failure to act may not only expose patients to injury but also affect the institution’s regulatory compliance posture and insurance risk profile.

What are the most important takeaways from Olympus Corporation’s bronchoscope labeling update?

• Olympus Corporation has issued a new global labeling update for its bronchoscopes following multiple serious injury reports, including one in the United States in 2025, tied to laser therapy, argon plasma coagulation, and high-frequency cauterization procedures.
• The voluntary medical device corrective action builds on a 2023 field update and aims to prevent endobronchial combustion during tracheobronchial therapeutic interventions.
• The revised bronchoscope safety protocols recommend maintaining oxygen levels below 40 percent, limiting energy output to under 40 watts, ensuring more than four centimeters of separation between the endoscope and endotracheal tube, and using suction to evacuate smoke.
• Olympus Corporation has warned that failure to comply with the updated bronchoscope instructions for use may result in internal burns, device breakage, extended hospitalizations, or fatal complications.
• Hospitals are being urged to retrain clinical staff, revise operating room protocols, and incorporate these updated guidelines into procedural checklists for all bronchoscopy procedures involving energy-based tools.
• Olympus emphasized that the labeling update should be treated as binding for regulatory compliance purposes and that further safety monitoring will continue as part of its post-market surveillance.